Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dicerna Pharmaceuticals : B. Riley Lowers Dicerna Pharmaceuticals' PT to $35 from $49 on Heels of Revised Corporate Strategy, Keeps Buy Rating

08/11/2021 | 09:08am EDT


© MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
10/20DICERNA PHARMACEUTICALS : Announces Results for PHYOX4, Single-Dose Study of Nedosiran in ..
AQ
10/19DICERNA PHARMACEUTICALS : Says Hyperoxaluria Treatment Met Safety Endpoint in Trial But Mi..
MT
10/19DICERNA PHARMACEUTICALS : Announces Results for PHYOX™4, Single-Dose Study of Nedosi..
BU
10/19Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hypero..
CI
10/15DICERNA PHARMACEUTICALS : Announces Data to Be Presented at American Society of Nephrology..
BU
10/14DICERNA PHARMACEUTICALS : to Present Phase 1 Data for Two Drug Candidates at Liver Disease..
MT
10/14DICERNA PHARMACEUTICALS : Announces Poster Presentations at American Association for the S..
BU
10/14Dicerna Pharmaceuticals, Inc. Announces Poster Presentations at American Association fo..
CI
10/12DICERNA PHARMACEUTICALS : Corporate Overview
PU
10/01DICERNA PHARMACEUTICALS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 179 M - -
Net income 2021 -144 M - -
Net cash 2021 501 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Capitalization 1 697 M 1 697 M -
EV / Sales 2021 6,70x
EV / Sales 2022 6,71x
Nbr of Employees 302
Free-Float 91,8%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | DRNA | US2530311081 | MarketScreener
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 21,83 $
Average target price 30,89 $
Spread / Average Target 41,5%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagán Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.-0.91%1 697
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE241.44%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS18.47%59 196
VERTEX PHARMACEUTICALS-22.35%48 536